Core Insights - Nyxoah reported strong financial and operational results for Q4 and full year 2025, highlighting a successful U.S. commercialization launch and positive feedback from surgeons and patients [2][5][9] Financial Performance - Q4 2025 gross revenue reached €6.3 million, with net revenue of €5.6 million, reflecting a 347% year-over-year growth [5][8] - Full year 2025 gross revenue was €11.0 million, resulting in net revenue of €10.0 million, a 122% increase compared to 2024 [9] - The gross margin for Q4 2025 was approximately 64%, while the full year gross margin was around 63% [5][11] Cost Structure - Cost of goods sold for Q4 2025 was €2.0 million, leading to a gross profit of €3.6 million [10] - For the full year, cost of goods sold totaled €3.7 million, with a slight decrease in gross margin from 66% in 2024 to 63% in 2025 due to increased sales volume and operational ramp-up [11] Research and Development - R&D expenses for Q4 2025 were €10.9 million, down from €11.8 million in Q4 2024 [12] - Full year R&D expenses increased to €42.8 million from €34.3 million in 2024, driven by clinical expansion and product development [12] Selling, General and Administrative Expenses - SG&A expenses for Q4 2025 were €12.5 million, compared to €8.1 million in Q4 2024 [13] - For the full year, SG&A expenses rose to €48.3 million from €28.5 million in 2024, reflecting the build-out of the U.S. commercial organization [13] Operating Loss - The operating loss for Q4 2025 was €18.6 million, slightly higher than €18.3 million in Q4 2024 [14] - The total operating loss for the full year was €83.5 million, compared to €58.8 million in 2024, attributed to increased commercialization investments and clinical initiatives [14] Cash Position - As of December 31, 2025, cash, cash equivalents, and financial assets amounted to €48.0 million [15] U.S. Commercialization Strategy - The U.S. commercial launch of the Genio® system began in August 2025, with a focus on high-volume implanting centers and education for referral networks [3][6] - By the end of 2025, 145 surgeons had been trained, and 57 accounts activated in the U.S. [5][6] Future Revenue Guidance - The company anticipates U.S. net revenue for Q1 2026 to grow by approximately 25% over Q4 2025, with similar growth expected for Q2 2026 [24]

Core Viewpoint - Vivos Therapeutics, Inc. has announced that a recent study supports its belief that dental and facial morphology is directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in both adults and children [1][3]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues related to dentofacial abnormalities such as OSA and snoring [9]. - The company’s CARE devices have received FDA clearance for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [9]. Study Findings - The study titled "Correlation Between Severity of Obstructive Sleep Apnea and Dental Arch Form in Adults" indicates that small changes in dental and jaw morphology can lead to significant changes in airway function, with narrower intermolar distance and greater palatal height linked to higher Apnea-Hypopnea Index (AHI) [3][4]. - The study involved 100 participants, with the OSA group showing significantly narrower transverse intermolar distance and higher palatal height compared to controls, demonstrating a strong association (p<0.001) between these parameters and OSA severity [4]. Treatment Efficacy - Vivos-trained providers have successfully treated tens of thousands of OSA patients using Vivos CARE devices, with many patients completing treatment in less than 12 months and experiencing little to no remaining OSA symptoms [2]. - The unique mechanism of action in Vivos CARE devices allows for gradual redevelopment and repositioning of dental arches and jaws, potentially leading to lasting results [5]. Market Context - OSA affects over 1 billion people globally, with 80% remaining undiagnosed. The condition is linked to various chronic health issues, and traditional treatments like CPAP often fail to address root causes [10]. - The company estimates that several million Americans will undergo sleep tests this year, with nearly half likely to test positive for OSA, highlighting a significant market opportunity for Vivos devices [8].

Company Overview - Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA) [3] - The company's lead product is the Genio system, which is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA [3] Recent Developments - Nyxoah will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference from March 16 to 19, 2026 [1] - CEO Olivier Taelman will present on March 16, 2026, at 8:40 am ET, with a webcast available on the company's Investor Relations website [2] - The company will also hold one-on-one meetings with institutional investors during the conference [2] Product Milestones - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021 [4] - The company received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study [4] - The FDA approved the Genio system for a subset of adult patients with moderate to severe OSA in August 2025 [4]

Core Insights - Nyxoah has signed a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC) to enhance Obstructive Sleep Apnea (OSA) therapy management and improve access to its Genio® therapy in the Middle East [1][2] Group 1: Partnership and Strategic Focus - The MoU aims to position SSMC as a leading regional center for Genio therapy, focusing on developing a high-volume implant program centered on patient care [2] - The collaboration includes establishing SSMC as a training hub for Genio therapy, educating surgeons, sleep physicians, and healthcare professionals across the region [3] Group 2: Clinical and Research Initiatives - Discussions are ongoing to explore clinical research and collaboration in sleep apnea and chronic disease management [3] - The initiative aligns with Nyxoah's vision to provide new treatment options for OSA patients and investigate the impact of advanced OSA management on chronic diseases like type 2 diabetes [4] Group 3: Company Overview and Product Information - Nyxoah specializes in developing innovative solutions for OSA, with its lead product being the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy [5] - The Genio system received its European CE Mark in 2019 and has expanded its therapeutic indications following successful studies, including the BETTER SLEEP study and DREAM IDE pivotal study [6]

Core Viewpoint - Vivos Therapeutics, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $4.64 million to support its operations in the sleep-related breathing disorder market, particularly obstructive sleep apnea (OSA) [1][4]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues, particularly OSA and snoring [7]. - The company’s devices have received FDA clearance for treating OSA in adults and children aged 6 to 17, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. Market Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed, highlighting a significant market opportunity for innovative treatments [8]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for more effective solutions [8]. Financial Activity - The company exercised warrants to purchase up to 1,982,356 shares at a reduced price of $2.34 per share, originally priced between $3.83 and $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. Use of Proceeds - The net proceeds from the warrant exercise will be utilized for working capital and general corporate purposes [4].

Core Insights - Nyxoah has announced the commercial launch of its Genio® system in the Netherlands, with successful implants performed at OLVG West and Zuyderland hospitals [1][2] - The Genio system is designed as a breakthrough therapy for Obstructive Sleep Apnea (OSA), providing an alternative for patients who cannot tolerate CPAP [2][3] - The launch reflects Nyxoah's ongoing expansion in Europe and the growing adoption of its bilateral, externally powered Genio therapy [2] Company Overview - Nyxoah is a medical technology company focused on innovative solutions for treating OSA, with its lead product being the Genio system, which is leadless and battery-free [3] - The company aims to improve the quality of life for OSA patients, who face increased mortality risk and cardiovascular issues [3] Product Features - The Genio system stimulates both branches of the nerve, is MRI-compatible, and can be upgraded via an external activation chip, making it a promising long-term solution [2] - The absence of an implanted battery and reliable performance in the supine position are highlighted as significant advantages of the Genio system [2] Regulatory Milestones - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah has also completed IPOs on Euronext Brussels and NASDAQ, and received FDA approval for a subset of adult patients with moderate to severe OSA in August 2025 [4]

Core Insights - Vivos Therapeutics, Inc. is expanding its operations with the grand opening of a new sleep testing and treatment center in Auburn Hills, Michigan, as part of its national expansion strategy to address obstructive sleep apnea (OSA) [1][3] - The new center operates under a capital-efficient affiliation model, allowing Vivos to partner with existing sleep clinics rather than solely relying on acquisitions, which enhances scalability and reduces capital intensity [2][4] - Vivos aims to provide innovative diagnostic and therapeutic solutions for OSA patients, leveraging its proprietary FDA-cleared products to improve patient outcomes and generate higher revenue for affiliated practices [3][4] Company Overview - Vivos Therapeutics focuses on developing and commercializing diagnostic and treatment methods for sleep-related breathing disorders, particularly OSA, with FDA-cleared devices for both adults and children [6][8] - The company emphasizes a non-invasive and non-pharmaceutical approach to treating OSA, known as The Vivos Method, which aims to address the root causes of the disorder rather than relying on traditional treatments like CPAP [9][7] Market Context - OSA affects over 1 billion people globally, with a significant portion undiagnosed, highlighting a substantial market opportunity for Vivos to provide effective treatments [7] - The sleep testing industry has faced pricing pressures, leading to closures and consolidations, which Vivos aims to counteract by offering differentiated treatment options through strategic affiliations [4][5]

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its third quarter 2025 financial results and will discuss strategic collaborations that may impact revenue growth and cash burn during a conference call scheduled for November 19, 2025 [1][2]. Company Overview - Vivos Therapeutics, Inc. specializes in medical devices and healthcare services for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [5]. - The company has developed proprietary treatments and diagnostic procedures, with its devices cleared by the FDA for various severity levels of OSA in both adults and children [5]. - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [5]. Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [6]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [6]. Strategic Initiatives - Vivos aims to enhance its market position through technology, education, and collaborations with sleep healthcare providers to better address OSA patients' needs [7]. - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [8].

Inspire Medical Systems, Inc. November 2025 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' "future," "outlook," ''intend,'' ''target,'' ''project,'' ''contemplate ...

Core Insights - Nyxoah SA will participate in the Stifel 2025 Healthcare Conference on November 11, 2025, presenting at 9:20 AM Eastern Time via webcast [2][3] Company Overview - Nyxoah is a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), with its lead product being the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy [4] - The Genio system received its European CE Mark in 2019 following the successful BLAST OSA study and has since expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients [5] - The company completed IPOs on Euronext Brussels in September 2020 and NASDAQ in July 2021, and received U.S. FDA approval for a Premarket Approval application in August 2025 [5]